CSPC's JMT202 receives U.S. clinical trial approval

CSPC Pharmaceutical Group Limited (HKEX: 1093) announced that its JMT202, a recombinant fully human anti-β Klotho monoclonal antibody drug, has received approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials in the United States. The drug, already undergoing clinical trials in China following approval from the National Medical Products Administration in May 2024, is designed as an FGFR1c/β Klotho receptor agonist. JMT202 aims to treat metabolism-related diseases, including dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and obesity. The clinical trial indication specifically targets hypertriglyceridemia (HTG). Preclinical studies have indicated that the drug reduces triglyceride levels with a good safety profile and long dosing intervals, potentially offering significant clinical benefits.